NIH Revises Treatment Guidelines for Ivermectin for the Treatment of COVID-19

Front Line COVID-19 Critical Care Alliance (FLCCC Alliance)

Newswise — NEW YORK, NEW YORK: —JANUARY 14, 2021:  One week after Dr. Paul Marik and Dr. Pierre Kory—founding members of the Front Line Covid-19 Critical Care Alliance (FLCCC)— along with Dr. Andrew Hill, researcher and consultant to the World Health Organization (WHO), presented their data before the NIH Treatment Guidelines Panel, the NIH has upgraded their recommendation on ivermectin, making it an option for use in COVID-19. 

This new designation upgraded the status of ivermectin from “against” to “neither for nor against”, which is the same recommendation given to monoclonal antibodies and convalescent plasma, both widely used across the nation. 

By no longer recommending against ivermectin use, doctors should feel more open in prescribing ivermectin as another therapeutic option for the treatment of COVID-19. This may clear its path towards FDA emergency use approval. 

“Ivermectin is one of the world’s safest, cheapest and most widely available drugs,” noted Dr. Kory, President of the FLCCC Alliance. “The studies we presented to the NIH revealed high levels of statistical significance showing large magnitude benefit in transmission rates, need for hospitalization, and death. What’s more, the totality of trials data supporting ivermectin is without precedent.” 

In its ivermectin recommendations update, the NIH also indicated they will continue to review additional trials as they are released. “We are encouraged that the NIH has moved off of its August 27 recommendation against the use of ivermectin for COVID-19,” continued Kory. “That recommendation was made just as the numerous compelling studies for ivermectin were starting to roll in. New studies are still coming in, and as they are received and reviewed, it is our hope that the NIH’s recommendation for the use of ivermectin will be the strongest recommendation for its use as possible.” 

Current meta-analyses of studies of ivermectin from around the world show a compelling trend towards the drug’s potent benefits against SARS-CoV-2. Ivermectin, developed in 1975, led to the eradication of a “pandemic” of parasitic diseases across multiple continents and earned the 2015 Nobel Prize for Physiology or Medicine for its discoverers, Dr. William Campbell and Dr. Ōmura Satoshi. 

In related news, the manuscript written by the FLCCC has been accepted for publication, following a rigorous peer review, in Frontiers in Pharmacology.  The full paper will be published within the next couple of weeks, however the preview can be found here

 




Filters close

Showing results

110 of 5382
access_time Embargo lifts in 2 days
Embargo will expire: 14-Apr-2021 2:00 PM EDT Released to reporters: 12-Apr-2021 4:05 PM EDT

A reporter's PressPass is required to access this story until the embargo expires on 14-Apr-2021 2:00 PM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Newswise: Texas A&M researchers leaders in study of COVID-19 blocking enzyme
Released: 12-Apr-2021 4:05 PM EDT
Texas A&M researchers leaders in study of COVID-19 blocking enzyme
Texas A&M AgriLife

Collaborative study shows K777 effective in combatting SARS-CoV-2 virus

Released: 12-Apr-2021 3:05 PM EDT
Scientists Reveal COVID-19 News, Next Frontier in Fighting Substance Abuse, More
Federation of American Societies for Experimental Biology (FASEB)

Register for online access to cutting-edge science at Experimental Biology 2021, April 27–30

Released: 12-Apr-2021 3:05 PM EDT
Double-Lung Transplant After COVID-19 Performed in Canada
University Health Network (UHN)

Case done at University Health Network is believed to be a first in Canada on a patient whose lungs were irreparably damaged by COVID-19

Newswise: How Cedars-Sinai Prepared for Pandemic Patients
Released: 12-Apr-2021 1:05 PM EDT
How Cedars-Sinai Prepared for Pandemic Patients
Cedars-Sinai

When the COVID-19 pandemic hit, healthcare professionals around the globe had to quickly learn to stay safe

Newswise: Workplace Communication Study During Pandemic Finds Managers Should Talk Less, Listen More
Released: 12-Apr-2021 11:05 AM EDT
Workplace Communication Study During Pandemic Finds Managers Should Talk Less, Listen More
Baylor University

Managers should listen more, be empathetic and be sure they give feedback — even if they cannot solve a problem immediately, according to a Baylor University study that focused on workplace communication during the pandemic. The crisis highlighted the need for better on-the-job communication with employees now and in the future, when the pandemic recedes, researchers said.

Released: 12-Apr-2021 9:00 AM EDT
Pandemic Paradox: People Want to Improve Mental Health by Exercising, but Stress and Anxiety Get in the Way, Research Shows
McMaster University

The pandemic has created a paradox where mental health has become both a motivator for and a barrier to physical activity.

Newswise: NIEHS earns WELL building rating amid pandemic
Released: 12-Apr-2021 9:00 AM EDT
NIEHS earns WELL building rating amid pandemic
National Institute of Environmental Health Sciences (NIEHS)

On March 30, 2021, the National Institute of Environmental Health Sciences (NIEHS) became the first federal agency to achieve the International WELL Building Institute’s Health-Safety Rating.

access_time Embargo lifts in 2 days
Embargo will expire: 15-Apr-2021 4:00 PM EDT Released to reporters: 12-Apr-2021 9:00 AM EDT

A reporter's PressPass is required to access this story until the embargo expires on 15-Apr-2021 4:00 PM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Released: 12-Apr-2021 9:00 AM EDT
Large US study suggests survival benefit for severely ill COVID-19 patients treated with ECMO
Wolters Kluwer Health: Lippincott

For critically ill COVID-19 patients treated with extracorporeal membrane oxygenation (ECMO), the risk of death remains high – but is much lower than suggested by initial studies.


Showing results

110 of 5382

close
2.96456